Sitemap > Breaking Research > Cancer Immunotherapy
Displaying 1251 - 1300 of 1864 results
- Nanoparticles built by self-assembly of amphiphilic gamma-PGA can deliver antigens to antigen-presenting cells with high efficiency: A new tumor-vaccine carrier for eliciting effector T cells.
- TANK-binding kinase-1 delineates innate and adaptive immune responses to DNA vaccines.
- Cell sensitivity to reaferon in patients with renal cell cancer after reaferon therapy.
- Preclinical studies in rats and squirrel monkeys for safety evaluation of the bivalent anti-human T cell immunotoxin, A-dmDT390-bisFv(UCHT1).
- Local therapy of cancer with free IL-2.
- Delivery of mengovirus-derived RNA replicons into tumoural liver enhances the anti-tumour efficacy of a peripheral peptide-based vaccine.
- Trastuzumab and gemcitabine as salvage therapy in heavily pre-treated patients with metastatic breast cancer.
- A multicenter, phase II study of infliximab plus gemcitabine in pancreatic cancer cachexia.
- Sustained activation and tumor targeting of NKT cells using a CD1d-anti-HER2-scFv fusion protein induce antitumor effects in mice.
- CD70 as a therapeutic target in human malignancies.
- Elevated chemokine receptor CXCR4 expression in primary tumors following neoadjuvant chemotherapy predicts poor outcomes for patients with locally advanced breast cancer (LABC).
- Combined Therapy with Rituximab Plus Cyclophosphamide/Vincristine/Prednisone for Sjogren's Syndrome-Associated B-Cell Non-Hodgkin's Lymphoma.
- Targeted combinatorial therapy of non-small cell lung carcinoma using a GST-fusion protein of full-length or truncated MDA-7/IL-24 with Tarceva.
- A novel therapeutic fusion protein vaccine by two different families of heat shock proteins linked with HPV16 E7 generates potent antitumor immunity and antiangiogenesis.
- A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity.
- CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potential.
- Combination of Bevacizumab and Docetaxel in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer: A Phase 2 Study.
- PB183, a sigma receptor ligand, as a potential PET probe for the imaging of prostate adenocarcinoma.
- Cetuximab plus FOLFOX-4 for fully resected stage III colon carcinoma: scientific background and the ongoing PETACC-8 trial.
- Biweekly cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fluorouracil.
- Efficient identification of a novel cancer/testis antigen for immunotherapy using three-step microarray analysis.
- Profound but dysfunctional lymphangiogenesis via vascular endothelial growth factor ligands from CD11b+ macrophages in advanced ovarian cancer.
- Tissue inhibitor of metalloproteinase-3 via oncolytic herpesvirus inhibits tumor growth and vascular progenitors.
- Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer.
- Phase I Clinical Study of Atacicept in Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma.
- Oncolytic efficacy of recombinant vesicular stomatitis virus and myxoma virus in experimental models of rhabdoid tumors.
- Tumor-selective replication of an oncolytic adenovirus carrying oct-3/4 response elements in murine metastatic bladder cancer models.
- Yeast-Derived {beta}-Glucan Augments the Therapeutic Efficacy Mediated by Anti-Vascular Endothelial Growth Factor Monoclonal Antibody in Human Carcinoma Xenograft Models.
- The oncolytic adenovirus targeting to TERT and RB pathway induced specific and potent anti-tumor efficacy in vitro and in vivo for hepatocellular carcinoma.
- Appropriate Timing of CD40 Ligation for RNA-Pulsed DCs to Induce Antitumor Immunity.
- Roles of CXCL8 in squamous cell carcinoma proliferation and migration.
- Low-scale phosphoproteome analyses identify the mTOR effector p70 S6 kinase 1 as a specific biomarker of the dual-HER1/HER2 tyrosine kinase inhibitor lapatinib (Tykerb(R)) in human breast carcinoma cells.
- Generation of Affibody ligands binding the IL-2 receptor alpha.
- Review of Phase II Trial Designs Used in Studies of Molecular Targeted Agents: Outcomes and Predictors of Success in Phase III.
- Heterophilic NeuGcGM3 ganglioside cancer vaccine in advanced melanoma patients: Results of a Phase Ib/IIa Study.
- IL-21 induces in vivo immune activation of NK cells and CD8(+) T cells in patients with metastatic melanoma and renal cell carcinoma.
- Potent Oncolytic activity of human enteroviruses against human prostate cancer.
- Human immunodeficiency virus-induced apoptosis of human breast cancer cells via CXCR4 is mediated by the viral envelope protein but does not require CD4.
- Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma.
- Expression of ICOS on Human Melanoma-Infiltrating CD4+CD25highFoxp3+ T Regulatory Cells: Implications and Impact on Tumor-Mediated Immune Suppression.
- Radiation-Induced IFN-{gamma} Production within the Tumor Microenvironment Influences Antitumor Immunity.
- Knockdown of Mgat5 Inhibits Breast Cancer Cell Growth with Activation of CD4+ T Cells and Macrophages.
- Selection of an Antibody Library Identifies a Pathway to Induce Immunity by Targeting CD36 on Steady-State CD8{alpha}+ Dendritic Cells.
- Vaccination of a Melanoma Patient with Mature Dendritic Cells Pulsed with MAGE-3 Peptides Triggers the Activity of Nonvaccine Anti-Tumor Cells.
- Genetically engineered T cells expressing a HER2-specific chimeric receptor mediate antigen-specific tumor regression.
- Anti-tumor effect of pegylated interferon in the rat hepatocarcinogenesis model.
- Dexamethasone interferes with trastuzumab-induced cell growth inhibition through restoration of AKT activity in BT-474 breast cancer cells.
- Calix[4]arene Decorated with Four Tn Antigen Glycomimetic Units and P3CS Immunoadjuvant: Synthesis, Characterization, and Anticancer Immunological Evaluation.
- Production and characterization of highly tumor-specific rat monoclonal antibodies recognizing the extracellular domain of human l-type amino-acid transporter 1.
- Co-administration of carcinoembryonic antigen and HIV TAT fusion protein with CpG-oligodeoxynucleotide induces potent antitumor immunity.